AIM: To identify factors that may prevent or delay patients referred for consideration of phase I studies from commencing such a study. METHODS: A retrospective audit of phase I study referrals for the period 1st March to 31st August 2005 to the Drug Development Unit was performed. All reasons that led to either delay or recruitment failure were documented and analysed. RESULTS: Data from 176 patients (105M/71F) were analysed. Median age at referral was 59 years and median performance status (PS) was 1. Of these, 56 (32%) were successfully recruited in a phase I trial. The median time from trial allocation to commencement of treatment was 4.8 weeks. Poor or deteriorating PS was the reason for delay or recruitment failure in 43 (35%) of non-recruited patients. CONCLUSIONS: Poor or deteriorating PS was the most common factor limiting accrual to phase I trials. Better patients' selection on this basis might improve recruitment rates.
AIM: To identify factors that may prevent or delay patients referred for consideration of phase I studies from commencing such a study. METHODS: A retrospective audit of phase I study referrals for the period 1st March to 31st August 2005 to the Drug Development Unit was performed. All reasons that led to either delay or recruitment failure were documented and analysed. RESULTS: Data from 176 patients (105M/71F) were analysed. Median age at referral was 59 years and median performance status (PS) was 1. Of these, 56 (32%) were successfully recruited in a phase I trial. The median time from trial allocation to commencement of treatment was 4.8 weeks. Poor or deteriorating PS was the reason for delay or recruitment failure in 43 (35%) of non-recruited patients. CONCLUSIONS: Poor or deteriorating PS was the most common factor limiting accrual to phase I trials. Better patients' selection on this basis might improve recruitment rates.
Authors: Tira Tan; Michael Rheaume; Lisa Wang; Helen Chow; Anna Spreafico; Aaron R Hansen; Albiruni R A Razak; Lillian L Siu; Philippe L Bedard Journal: Oncologist Date: 2019-03-04
Authors: David M Hyman; Anne A Eaton; Mrinal M Gounder; Gary L Smith; Erika G Pamer; Martee L Hensley; David R Spriggs; Percy Ivy; Alexia Iasonos Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Syed F Zafar; Lance K Heilbrun; Prakash Vishnu; Pallavi Jasti; Raghu Venkatramanamoorthy; Li Ding; Patricia M Lorusso; Elisabeth I Heath Journal: J Geriatr Oncol Date: 2011-01-01 Impact factor: 3.599
Authors: Diane A J van der Biessen; Merlijn A Cranendonk; Gaia Schiavon; Bronno van der Holt; Erik A C Wiemer; Ferry A L M Eskens; Jaap Verweij; Maja J A de Jonge; Ron H J Mathijssen Journal: Oncologist Date: 2013-02-21
Authors: Howard A Zaren; Suresh Nair; Ronald S Go; Rebecca A Enos; Keith S Lanier; Michael A Thompson; Jinxiu Zhao; Deborah L Fleming; John C Leighton; Thomas E Gribbin; Donna M Bryant; Angela Carrigan; Jennifer C Corpening; Kimberly A Csapo; Eileen P Dimond; Christie Ellison; Maria M Gonzalez; Jodi L Harr; Kathy Wilkinson; Andrea M Denicoff Journal: J Oncol Pract Date: 2013-03 Impact factor: 3.840
Authors: Luis E Gonzalez; Steven K Sutton; Christie Pratt; Matthew Gilbertson; Scott Antonia; Gwendolyn P Quinn Journal: J Cancer Educ Date: 2013-09 Impact factor: 2.037
Authors: Nicole G Chau; Ana Florescu; Kelvin K Chan; Lisa Wang; Eric X Chen; Philippe Bedard; Amit M Oza; Lillian L Siu Journal: BMC Cancer Date: 2011-10-05 Impact factor: 4.430
Authors: David J Pinato; Chara Stavraka; Michael J Flynn; Martin D Forster; Séan M O'Cathail; Michael J Seckl; Rebecca S Kristeleit; David Olmos; Samantha J Turnbull; Sarah P Blagden Journal: PLoS One Date: 2014-01-07 Impact factor: 3.240
Authors: Joeri A J Douma; Laurien M Buffart; Ramy Sedhom; Mariette Labots; Willemien C Menke-van der Houven van Oordt; Mikkjal Skardhamar; Anthony De Felice; Esther Lee; Divya Dharmaraj; Nilofer S Azad; Michael A Carducci; Henk M W Verheul Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639